GSK’s (GSK) Neutral Rating Reiterated at Citigroup

Citigroup restated their neutral rating on shares of GSK (NYSE:GSK) in a research note released on Friday, MarketBeat.com reports.

GSK has been the subject of several other research reports. HSBC upgraded shares of GSK from a “reduce” rating to a “hold” rating in a research note on Monday, July 6th. Wall Street Zen upgraded shares of GSK from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Royal Bank Of Canada restated an “outperform” rating on shares of GSK in a research report on Tuesday, June 9th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of GSK in a research note on Thursday, July 9th. Finally, Weiss Ratings cut shares of GSK from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 11th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, GSK has an average rating of “Hold” and an average price target of $53.00.

GSK Price Performance

Shares of NYSE:GSK opened at $51.38 on Friday. The company’s fifty day moving average price is $51.58 and its 200 day moving average price is $53.42. The firm has a market capitalization of $103.92 billion, a P/E ratio of 13.35, a P/E/G ratio of 3.27 and a beta of 0.35. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. GSK has a 12 month low of $36.75 and a 12 month high of $61.69.

GSK Cuts Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, July 9th. Shareholders of record on Friday, May 15th were given a dividend of $0.44 per share. This represents a $1.76 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend was Friday, May 15th. GSK’s payout ratio is 46.49%.

Institutional Investors Weigh In On GSK

A number of large investors have recently modified their holdings of GSK. IHT Wealth Management LLC grew its position in GSK by 1.3% in the fourth quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock valued at $736,000 after acquiring an additional 188 shares in the last quarter. Bogart Wealth LLC lifted its position in shares of GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock worth $83,000 after purchasing an additional 200 shares during the last quarter. Coston McIsaac & Partners grew its position in shares of GSK by 17.3% in the 4th quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock worth $68,000 after acquiring an additional 206 shares in the last quarter. First Horizon Corp boosted its holdings in GSK by 78.7% in the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock worth $26,000 after purchasing an additional 236 shares during the period. Finally, NBT Bank N A NY grew its position in shares of GSK by 1.9% during the 1st quarter. NBT Bank N A NY now owns 16,568 shares of the pharmaceutical company’s stock valued at $914,000 after buying an additional 315 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Trending Headlines about GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: The FDA approved Jideytro for previously treated ROS1-positive non-small cell lung cancer, marking GSK’s first lung cancer approval and a new catalyst for its oncology pipeline. Article
• Positive Sentiment: Analysts and market commentary highlighted Jideytro’s approval as potentially undervalued, suggesting investors may be underestimating the earnings contribution from GSK’s precision oncology assets. Article
• Positive Sentiment: GSK also received approval in Canada for a prefilled syringe presentation of Shingrix, which should support vaccine convenience and commercial execution. Article
• Neutral Sentiment: Citigroup reaffirmed its neutral rating on GSK, indicating the approval news is positive but not enough to change the bank’s stance yet. Article

GSK Company Profile

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.